Codexis is a provider of enzyme technology and manufacturing solutions for the pharmaceutical and biotech industries. The company uses its proprietary CodeEvolver directed evolution platform to discover, optimize, and commercialize enzymes and proteins tailored for specific therapeutic applications. It operates in two primary segments: ECO Synthesis, which provides enzymatic tools and manufacturing services to enable large-scale production of RNA interference therapeutics as an alternative to traditional chemical synthesis methods; and pharma biocatalysis, where it supplies optimized enzymes to pharmaceutical manufacturers to improve efficiency and reduce waste in the production of small-molecule drugs. The company also licenses its technology platform to major pharmaceutical companies and has developed specialized enzymes for mRNA manufacturing, sequencing, diagnostics, and DNA synthesis. Codexis generates revenue through enzyme product sales, contracted research and development partnerships, upfront and milestone payments, licensing fees, and royalties on commercial products.